Thus, targeting IL-1β for cancer therapy should consider its dual effects by differential strategies such as blocking the chronic inflammation-driven pro-tumour effect and strengthening antigen-specific antitumour immunityin a tumour-antigen vaccine, CAR-T therapy and immune checkpoint (CTLA-4 and PD-1) blockade. Here, CTLA4 is linked to neoplasm.